Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liu D
Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,
Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,
Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Keywords: 177Lu-DOTATATE, metastases, quality of life,
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liberini V
Authors: Liberini V, Rampado O, Gallio E, De Santi B, Ceci F,
Keywords: radiomic, PRRT, NET, SSTR-RADS, NETPET grade, RECIST 1.1 criteria, 68Ga-DOTATOC PET/CT, tumor/spleen ratio, radiomic analysis of 68Ga-DOTATOC PET/CT, radiomic features,
#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors
Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Aberle S
Authors: Aberle S, Benz M, Grokovski R, Christ E, Nicolas G,
Keywords: PRRT, Re-challenge, 90Y-DOTATOC, 177Lu-DOTATOC, neuroendocrine tumor,